vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -60.3%, a 87.6% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs -49.9%). ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $1.6M). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs -6.7%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
ECBK vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $9.1M |
| Net Profit | $2.6M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 36.7% | -51.1% |
| Net Margin | 27.3% | -60.3% |
| Revenue YoY | 33.8% | -49.9% |
| Net Profit YoY | 79.5% | -184.8% |
| EPS (diluted) | $0.32 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $9.1M | ||
| Q3 25 | $8.8M | $17.9M | ||
| Q2 25 | $8.0M | $15.7M | ||
| Q1 25 | $6.9M | $10.1M | ||
| Q4 24 | $7.1M | $18.2M | ||
| Q3 24 | $6.6M | $18.0M | ||
| Q2 24 | $6.3M | $13.5M | ||
| Q1 24 | $6.2M | — |
| Q4 25 | $2.6M | $-5.5M | ||
| Q3 25 | $2.4M | $2.4M | ||
| Q2 25 | $1.4M | $164.0K | ||
| Q1 25 | $1.3M | $-3.6M | ||
| Q4 24 | $1.4M | $6.5M | ||
| Q3 24 | $1.1M | $3.2M | ||
| Q2 24 | $791.0K | $-2.2M | ||
| Q1 24 | $621.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 36.7% | -51.1% | ||
| Q3 25 | 37.0% | 11.9% | ||
| Q2 25 | 23.9% | 7.5% | ||
| Q1 25 | 24.9% | -41.0% | ||
| Q4 24 | 27.3% | 39.6% | ||
| Q3 24 | 23.3% | 22.2% | ||
| Q2 24 | 16.9% | -18.0% | ||
| Q1 24 | 13.4% | — |
| Q4 25 | 27.3% | -60.3% | ||
| Q3 25 | 27.7% | 13.2% | ||
| Q2 25 | 18.0% | 1.0% | ||
| Q1 25 | 18.7% | -35.8% | ||
| Q4 24 | 20.3% | 35.6% | ||
| Q3 24 | 17.2% | 18.0% | ||
| Q2 24 | 12.6% | -16.4% | ||
| Q1 24 | 10.0% | — |
| Q4 25 | $0.32 | $-0.06 | ||
| Q3 25 | $0.29 | $0.03 | ||
| Q2 25 | $0.17 | $0.00 | ||
| Q1 25 | $0.16 | $-0.05 | ||
| Q4 24 | $0.18 | $0.10 | ||
| Q3 24 | $0.14 | $0.03 | ||
| Q2 24 | $0.09 | $-0.03 | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $48.2M |
| Total Assets | $1.6B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $14.7M | ||
| Q3 25 | $201.9M | $13.6M | ||
| Q2 25 | $191.0M | $17.9M | ||
| Q1 25 | $143.7M | $19.5M | ||
| Q4 24 | $309.4M | $19.8M | ||
| Q3 24 | $114.8M | $27.4M | ||
| Q2 24 | $108.7M | $23.4M | ||
| Q1 24 | $109.8M | — |
| Q4 25 | $171.9M | $48.2M | ||
| Q3 25 | $169.3M | $52.9M | ||
| Q2 25 | $168.3M | $49.9M | ||
| Q1 25 | $168.6M | $45.2M | ||
| Q4 24 | $168.3M | $43.2M | ||
| Q3 24 | $166.0M | $32.4M | ||
| Q2 24 | $166.5M | $28.6M | ||
| Q1 24 | $165.8M | — |
| Q4 25 | $1.6B | $82.3M | ||
| Q3 25 | $1.6B | $82.3M | ||
| Q2 25 | $1.5B | $78.5M | ||
| Q1 25 | $1.5B | $73.9M | ||
| Q4 24 | $1.4B | $73.4M | ||
| Q3 24 | $1.4B | $61.6M | ||
| Q2 24 | $1.3B | $91.5M | ||
| Q1 24 | $1.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $2.0M |
| Free Cash FlowOCF − Capex | $9.0M | $1.6M |
| FCF MarginFCF / Revenue | 94.7% | 17.8% |
| Capex IntensityCapex / Revenue | 2.2% | 4.4% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $2.0M | ||
| Q3 25 | $4.0M | $-3.7M | ||
| Q2 25 | $1.9M | $-5.2M | ||
| Q1 25 | $-631.0K | $-5.1M | ||
| Q4 24 | $6.2M | $4.0M | ||
| Q3 24 | $861.0K | $4.1M | ||
| Q2 24 | $1.4M | $-3.6M | ||
| Q1 24 | $-429.0K | — |
| Q4 25 | $9.0M | $1.6M | ||
| Q3 25 | $4.0M | $-4.2M | ||
| Q2 25 | $1.8M | $-5.7M | ||
| Q1 25 | $-649.0K | $-5.4M | ||
| Q4 24 | $6.2M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $1.3M | $-3.8M | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | 17.8% | ||
| Q3 25 | 44.9% | -23.7% | ||
| Q2 25 | 23.0% | -36.2% | ||
| Q1 25 | -9.4% | -53.0% | ||
| Q4 24 | 86.8% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | 21.4% | -28.1% | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | 4.4% | ||
| Q3 25 | 0.8% | 2.8% | ||
| Q2 25 | 0.6% | 2.8% | ||
| Q1 25 | 0.3% | 3.0% | ||
| Q4 24 | 0.8% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.6% | 1.3% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | -1.58× | ||
| Q2 25 | 1.32× | -31.91× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | 0.61× | ||
| Q3 24 | 0.76× | 1.27× | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECBK
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
